Daniel Ciznadija

Daniel Ciznadija

Work History

Work History
Jan 2007 - Jun 2012

Research Associate

Memorial Sloan-Kettering Cancer Center

Demonstrated how genetic and therapeutic inhibition of the cyclin D1-CDK4 kinase impacts glioma formation and maturation of the tumor microenvironment, an essential step for applying CDK inhibitors clinically.

Key Achievements:

* Led multi-disciplinary research team assessing therapeutic inhibition of CDK4 for treatment of glioma.* Validated the novel role of cyclin D1 and CDK4 in PDGF-mediated glioma using state-of-the-art RCAS-tvA   

  mouse system for somatic gene transfer.* Developed protocol for isolation of primary microglial (immune) cells from murine cortices.* Generated in vitro cell line surrogates to study the role of cyclin D1 and CDK4 in glioma.* Core organizer of the institutional postdoctoral symposium (new format still in use today).* Speaker (invited) for numerous seminars and panels on effective presentation skills.* Supervised 3 graduate/summer research students.* Executed immunofluorescence and flow-based assays to identify a function for cyclin D1 and CDK4 in

  glioma and microglial cell biology.

Oct 2005 - Jan 2007

Senior Research Officer

Sienna Cancer Diagnostics Ltd.

Improved and fast-tracked novel biomarker assay to detect and monitor different malignancies

Key achievements:

* Optimized work-flow between company and clinical stake-holders to obtain and analyze biological 

  specimens and achieve program milestones ahead of schedule.* Increased biomarker assay sensitivity 2-3-fold by maximizing variability in substrate usage, contributing to

  the award of a provisional patent on novel biosensor technologies.* Oversaw and facilitated transfer of biomarker assay to contract research organization (Cancer Trials

  Australia).* Managed the transition to new laboratory space and training of incoming technicians.


Mar 2000 - Feb 2005


University of Melbourne